Lexaria Bioscience Corp. (NASDAQ:LEXX) announced on September 30, 2025 that it had closed a registered direct offering priced at‑the‑market under Nasdaq rules, issuing 2,666,667 shares of common stock at a purchase price of $1.50 per share. The transaction generated approximately $4.0 million in gross proceeds for the company.
In addition to the share sale, Lexaria completed a concurrent private placement of unregistered warrants, allowing the holder to purchase up to 2,666,667 shares of common stock at an exercise price of $1.37 per share. The warrants are immediately exercisable and expire five years from the effective date of the resale registration statement.
The company stated that the net proceeds from the offering will be used for working capital and other general corporate purposes, including ongoing research and development and business development initiatives. This financing provides Lexaria with additional liquidity to support its drug‑delivery platform and related clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.